Fig. 5From: Retrospective analysis of safety and efficacy of enhanced recovery pathways in stage II–III colorectal cancer patients submitted to surgery and adjuvant therapyEuropean Organization for Research and Treatment questionnaires score. The mean differences in QLQ-C30/CR38 (quality of life questionnaires-cancer specific 30/colorectal cancer specific 38) score of 10 or more points was considered as clinically significant difference. *Clinically significant lower QLQ-C30/CR38 score/patient than those of FTLCO cohortBack to article page